Latest Conference Articles

This interview at the Skin of Color Society (SOCS) Scientific Symposium features Elbuluk describing her plans as newly-elected president of SOCS.

An analysis of data from the DELTA program at AAD 2025 sheds light on the efficacy of delgocitinib for chronic hand eczema.

Crystal Aguh, MD, discusses a study from AAD 2025 examining HbA1c levels and outcomes in CCCA.

This interview with Chovatiya highlights his portion of the ‘Skin of Color’ talk at the American Academy of Dermatology conference.

Data at AAD 2025 and an announcement from Amgen provide insight into the potential role of rocatinlimab in atopic dermatitis.

This interview with Snyder features a discussion on recent findings on remibrutinib among patients with chronic spontaneous urticaria, also known as CSU.

New data from AAD 2025 and topline results from the ICONIC program underline the potential of icotrokinra in moderate to severe plaque psoriasis.

Robert Bissonnette, MD, discusses data from the ICONIC-LEAD trial and the potential role of icotrokinra in plaque psoriasis.

In this interview at AAD 2025, Craiglow speaks on her team’s late-breaking findings on baricitinib among adolescents with severe alopecia areata.

Data from AAD 2025 examine the effect of GLP-1 RAs on HS among patients with overweight or obesity.

Phase 3 data from ruxolitinib cream 1.5% presented at AAD 2025 demonstrate the potential of the topical agent in prurigo nodularis.

Stein Gold highlights her team's findings on tapinarof cream (Vtama) 1% from the 48-week ADORING 3 extension for those aged 2 to 17 with atopic dermatitis.

David Rosmarin, MD, discusses results from ADORING 3 presented at AAD 2025.

Susan Taylor, MD, discusses a study examining the effect of GLP-1 RA use relative to nonuse in central centrifugal cicatricial alopecia at AAD 2025.

This AAD 2025 interview features a discussion with Sonja Ständer, MD, new phase 3 findings from OLYMPIA 1 and 2 on nemolizumab in patients with prurigo nodularis.

New 3-year data from ADjoin demonstrate the efficacy and safety profile of lebrikizumab in moderate to severe atopic dermatitis.

HCPLive spoke with Anagnostou at AAAAI on how to determine what food allergy treatment patients should undergo.

Chambliss and colleagues found a 1% increase in asthma-related emergency department visits per unit of distance to semiconductor fabrication plants.

Interim phase 2 data suggest bimiralisib could help patients with actinic keratosis achieve complete or partial clearance of lesions in as little as 2 weeks.

Combined analysis of data from a pair of post-registrational studies demonstrate the clinical profile and patient opinion on treatment with tirbanulin.

At AAAAI, Golden discussed when to test for insect sting allergies, the role of venom immunotherapy, and the potential impact of epinephrine nasal spray.

In this interview at AAD 2025, Silverberg discusses important facts for dermatologists to know in the management of molluscum contagiosum.

At AAAAI 2025, David Golden, MD, discussed when to test for insect sting allergies, the role of mast cell disorders, and updated guidelines for all ages.

Eapen discussed her research into analyzing the cord blood methylome for markers that predict atopic dermatitis risk at the AAAAI/WAO Joint Congress.

In this interview, Aguh answers several key questions about the efforts of the Skin of Color Society and improving diversity in clinical research.

HCPLive spoke with Golden at AAAAI on the pitfalls of diagnosing all patients with insect stings for insect sting allergies.

A panel discussion at the Skin of Color Society Scientific Symposium features 3 notable speakers highlighting dermatology residency questions and more.

Casale discussed data from the phase 3 LIBERTY-CSU CUPID studies evaluating dupilumab’s use in urticaria.